C12Y 304/24087
Adamts13 endopeptidase
Official title: ADAMTS13 endopeptidase (3.4.24.87)
C12Y304/24087 (Adamts13 endopeptidase) appears on 48 US grants and 77 published applications in this corpus.
Search patents in C12Y- Granted patents
- 48
- Published applications
- 77
- Assignees
- 28
- Inventors
- 106
- Latest grant
- 4 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2002 | 0 | 1 |
| 2003 | 0 | 0 |
| 2004 | 0 | 0 |
| 2005 | 1 | 1 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 1 |
| 2009 | 1 | 3 |
| 2010 | 0 | 0 |
| 2011 | 1 | 4 |
| 2012 | 1 | 3 |
| 2013 | 1 | 1 |
| 2014 | 7 | 6 |
| 2015 | 3 | 6 |
| 2016 | 6 | 3 |
| 2017 | 5 | 5 |
| 2018 | 4 | 7 |
| 2019 | 3 | 6 |
| 2020 | 5 | 3 |
| 2021 | 1 | 3 |
| 2022 | 1 | 3 |
| 2023 | 5 | 10 |
| 2024 | 1 | 2 |
| 2025 | 1 | 4 |
| 2026 | 1 | 5 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- ADAMTS13 protein variants and uses thereof4 Aug 2026US 12,698,494 B2Sanquin IP B.V.
- Methods of purifying recombinant ADAMTS13 and other proteins and compositions thereof9 Dec 2025US 12,492,390 B2Takeda Pharmaceutical Company Limited
- Stabilized liquid and lyophilized ADAMTS13 formulations31 Dec 2024US 12,178,861 B2Takeda Pharmaceutical Company Limited
- Subcutaneous administration of ADAMTS1310 Oct 2023US 11,779,635 B2Takeda Pharmaceutical Company Limited
- Method of producing recombinant high molecular weight vWF in cell culture10 Oct 2023US 11,780,904 B2Takeda Pharmaceutical Company Limited
- Stabilized liquid and lyophilized adamts13 formulations8 Oct 2026US 2026/0306593 A1Takeda Pharmaceutical Company Limited
- Adamts13 protein variants and uses thereof8 Oct 2026US 2026/0308560 A1Sanquin IP B.V.
- Dual-specific binding molecule useful for isolating specific blood cells16 Apr 2026US 2026/0102719 A1ImmunityBio, Inc.
- Method for treating sepsis and related diseases2 Apr 2026US 2026/0092101 A1The Regents of the University of Colorado, a body corporate
- Methods of purifying recombinant adamts13 and other proteins and compositions thereof5 Mar 2026US 2026/0062691 A1Takeda Pharmaceutical Company Limited
Most cited
By later US patents
- Targeted augmentation of nuclear gene output25US 9,976,143 B2Cold Spring Harbor Laboratory · 2018
- Methods for expressing ADAMTS proteins in cell culture medium supplemented with zinc24US 8,313,926 B2Baxter Healthcare S. A. · 2012
- Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV19US 6,926,894 B2Baxter Aktiengesellschaft · 2005
- Method of producing a polypeptide or virus of interest in a continuous cell culture19US 8,580,554 B2Baxter Healthcare S. A. · 2013
- Method of producing recombinant high molecular weight vWF in cell culture17US 8,852,888 B2Baxter Healthcare S. A. · 2014